The heart valve repair and replacement market is witnessing dynamic advancements propelled by cutting-edge technologies. Innovations such as transcatheter aortic valve replacement (TAVR) and minimally invasive procedures are revolutionizing treatment approaches, offering patients less invasive options and quicker recovery times. Furthermore, the integration of 3D printing allows for personalized valve replacements, enhancing efficacy and patient outcomes. The market's growth trajectory is also fueled by increasing awareness, rising prevalence of cardiovascular diseases, and aging populations globally. These advancements signify a promising era in cardiac care, marking a paradigm shift towards precision medicine and improved quality of life.
Data Bridge Market Research analyses that the Global Heart Valve Repair and Replacement Market size was valued at USD 4,970.53 million in 2023, is projected to reach USD 11,585.65 million by 2031, with the CAGR of 11.3% in the forecast period of 2024 to 2031.
To know more about the study, visit: https://www.databridgemarketresearch.com/jp/reports/global-heart-valve-repair-and-replacement-market
Below are the Top Five Heart Valve Repair and Replacement Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Abbott
|
Abbott is a leading player in the heart valve repair and replacement market, offering a comprehensive portfolio of innovative products and solutions. Their transcatheter aortic valve replacement (TAVR) systems, such as the SAPIEN and PORTICO valves, are renowned for their efficacy and safety in treating aortic valve stenosis. Abbott's MitraClip device revolutionizes mitral valve repair, providing a minimally invasive alternative to surgery for patients with mitral regurgitation. Their commitment to advancing cardiovascular care through cutting-edge technology and clinical excellence cements Abbott's position as a cornerstone in the heart valve therapy landscape, dedicated to improving patient outcomes and quality of life.
|
|
Europe, Middle East and Africa, and Asia-Pacific, America,
|
In April 2021, Abbott announced that it had received CE mark for TriClip Trans catheter tricuspid valve repair system in Europe to treat tricuspid regurgitation. This will help the company in diversifying its business.
|
|
2.
|
Edwards Lifesciences Corporation
|
Edwards Lifesciences Corporation is a pioneering force in the heart valve repair and replacement market, renowned for its groundbreaking transcatheter heart valves (THVs). Their flagship product, the Edwards SAPIEN valve, has transformed the treatment landscape for aortic stenosis, offering a minimally invasive alternative to surgical valve replacement. Edwards' dedication to innovation extends to their diverse portfolio of products, including the Pascal system for mitral valve repair and the Harpoon system for beating heart mitral valve repair. With a relentless focus on patient outcomes and technological advancement, Edwards Lifesciences continues to shape the future of cardiovascular care.
|
|
Europe, Middle East and Africa, and Asia-Pacific, North America, South America
|
In July 2020, Edwards Lifesciences Corporation announced that it had received FDA approval for Resilia aortic valved conduit to implant solution for the bio-bentall procedure. It is a surgery that involves the replacement of patient’s aortic root, aortic valve, and ascending aorta. This approval will help the company to increase its revenue in coming years further.
|
|
3.
|
Medtronic
|
Medtronic is a global leader in the heart valve repair and replacement market, renowned for its transformative transcatheter and surgical solutions. The Medtronic CoreValve and Evolut TAVR systems provide minimally invasive alternatives to traditional aortic valve replacement, offering improved outcomes and faster recovery for patients with aortic stenosis. Additionally, Medtronic's portfolio includes the Intrepid transcatheter mitral valve replacement system, advancing treatment options for patients with mitral valve disease. With a legacy of innovation and a commitment to patient-centric care, Medtronic continues to drive progress in cardiovascular medicine, empowering clinicians to deliver optimal outcomes for their patients.
|
|
Europe, Middle East and Africa, and Asia-Pacific, North America, South America
|
In April 2021, Medtronic announced that it had received FDA device designation status for Emprint Ablation Catheter Kit. The kit is intended to be used with a microwave and lung navigation platform to provide minimally invasive. This will help the company in gaining the market in the coming years.
|
|
4.
|
BIOTRONIK SE & Co. KG
|
BIOTRONIK SE & Co. KG is a leading innovator in the heart valve repair and replacement market, specializing in transcatheter solutions for aortic and mitral valve disease. The BIOTRONIK SE & Co. KG Orsiro stent system offers exceptional outcomes in coronary interventions, complementing their transcatheter heart valve portfolio. BIOTRONIK's efforts in the heart valve space extend to their innovative Tricento transcatheter mitral valve replacement system, providing a promising solution for patients with mitral regurgitation. With a focus on precision engineering and clinical excellence, BIOTRONIK continues to push the boundaries of cardiovascular technology, ensuring that patients receive the highest standard of care.
|
|
Germany
|
In December 2020, BIOTRONIK SE & Co.KG announced FDA clearance and the availability of the Vital Data Sensor in the new BIOMONITOR IIIm injectable cardiac monitor (ICM). This sensor identifies body temperature increases potentially linked to fever, providing physicians with daily reports on vital data, aiding in remote patient monitoring and treatment adjustments. The BIOMONITOR IIIm integrates sensor technologies to measure patient activity, heart rate, and body temperature, recognizing the interrelationship between these vital signs and health conditions, notably fever's impact on heart rate and activity levels.
|
|
5.
|
Meril Life Sciences Pvt. Ltd.
|
Meril Life Sciences Pvt. Ltd. is an emerging player in the heart valve repair and replacement market, dedicated to developing innovative medical devices that address unmet clinical needs. Their portfolio includes transcatheter heart valve systems designed to provide minimally invasive treatment options for patients with valvular heart disease. Meril's focus on affordability and accessibility ensures that their products reach patients in both developed and developing regions, expanding access to life-saving treatments. By leveraging cutting-edge technology and clinical expertise, Meril is poised to make significant contributions to the advancement of cardiac care globally.
|
|
Europe, Middle East and Africa, and Asia-Pacific, North America, South America
|
In September 2020, Meril Life Sciences Pvt. Ltd. partnered with Zee Business for their edition ‘Aapki Khabar Aapka Fayeda’. This will help the company to create awareness about the prevalence of cardiovascular diseases, symptoms, causes and advancement to treat the disease.
|
Conclusion
The heart valve repair and replacement market exhibits promising growth prospects, fueled by a confluence of factors. Technological advancements, such as minimally invasive procedures and innovative valve designs, drive the market forward, enhancing patient outcomes and expanding treatment options. Moreover, the increasing prevalence of cardiovascular diseases, coupled with aging populations worldwide, presents a substantial market opportunity. As healthcare systems prioritize cardiac care and patients seek improved quality of life, the market for heart valve repair and replacement is poised for sustained expansion, offering both medical advancements and economic opportunities.
